Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.

PloS one - 1 Jan 2020

Tsukumo Yoshinori, Naito Mikihiko, Suzuki Takayoshi

Abstract excerpt

In non-small cell lung cancer (NSCLC), oncogenic driver mutations including those in KRAS and EGFR are typically mutually exclusive. However, recent reports indicate that multiple driver mutations are found in a certain percentage of cancers, and that the therapeutic responses of such cases with co-mutations of driver genes are largely unclear. Here, using CRISPR-Cas9-mediated genome editing, we generated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Clone Cells
Share to CRISPR-Associated Protein 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Gene Dosage

Share to Gene Editing

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 32130260
DOI: 10.1371/journal.pone.0229712
PMCID: PMC7055889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.PMID 32130260Read ↗

CRISPR-mediated modulation of EGFR signaling in lung cancer.Semantic proximity Read ↗

Potential CRISPR/Cas9 Gene Editing Applications in Reversing Acquired Resistance to EGFR-TKIs due to Secondary and Tertiary Mutations to EGFR in NSCLCSemantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.Semantic proximity Read ↗

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].Semantic proximity Read ↗

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Semantic proximity Read ↗

CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer.Semantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.Semantic proximity Read ↗

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.